Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation

NCT ID: NCT05042505

Last Updated: 2025-06-13

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-01-01
• Study Completion Date: 2025-11-01

Brief Summary

Patients with pre-transplantation type 2 diabetes (T2D) and new-onset diabetes post liver transplantation (NODAT) are managed with multiple doses of subcutaneous insulin (MSI) following liver transplantation. As these patients receive oral glucocorticoids (mostly prednisolone) and immunosuppressants, which elevate blood glucose levels, multiple doses of insulin are usually required. After 2-3 months, when steroid doses are tapered and doses of immunosuppressants stabilize, insulin requirements subside and several oral hypoglycemic agents are initiated, such as metformin and sitagliptin. However, these agents are prescribed off-label as the data regarding the safety and efficacy of these agents in patients with liver transplantation are scarce.

Furthermore, several patients with liver transplantation develop fatty liver (liver steatosis) several months after transplantation, which is a risk factor for liver dysfunction. SGLT-2 inhibitors are reported to have favorable effect on liver fat accumulation in patients with T2D. However, the effect of SGLT-2 inhibitor on liver fat accumulation after liver transplantation has not been evaluated.

Chronic liver disease is associated with changes in body composition, especially increase in visceral fat and decrease in skeletal muscle mass. Data regarding the changes in body composition following liver transplantation are scarce.

In this RCT, Investigators aim to evaluate the effect of dapagliflozin vs sitagliptin on liver fat accumulation; body composition variables; and safety and efficacy of these oral hypoglycemic agents in patients with diabetes and liver transplantation

Detailed Description

To study the effect of dapagliflozin vs sitagliptin on liver fat accumulation in patients with diabetes and liver transplantation.

Material and Methods Ethical considerations The trial protocol is approved by the Medanta ethics committees. The trial will be conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines. All the patients will be provided with written informed consent before participation.

Patients and study area A total of 100 patients will be enrolled for the study. Consecutive patients undergoing liver transplantation and attending outpatient Department of Endocrinology and Diabetes for management of diabetes mellitus will be enrolled. Diabetes mellitus will include both pre-transplantation type 2 diabetes as well as new-onset diabetes after transplantation (NODAT).

Statistical Analysis Plan:

The analysis will include profiling of patients on different demographic, clinical and laboratory parameters etc. Quantitative data will be presented in terms of means and standard deviation and qualitative/categorical data will be presented as absolute numbers and proportions. Cross tabulation will be generated and chi square test will be used for testing of association. Student t test will be used for comparison of quantitative outcome parameters and standard normal deviate test for proportions. P-value < 0.05 is considered statistically significant. SPSS software will be used for analysis.

Eligibility criteria Inclusion criteria

1. Diagnosis of diabetes (pre-transplantation type 2 diabetes or new onset diabetes after transplantation)

2. Subjects taking insulin and/or metformin and/or sulfonylurea for at least 3 months since liver transplantation

3. Body mass index (BMI) more than or equal to 18.5 kg/m2

Exclusion criteria

1. Type 1 diabetes

2. Estimated glomerular filtration rate (eGFR) <45 ml/min/1.73 m2, calculated by the Chronic Kidney Disease - Epidemiology (CKD-EPI) equation

3. Liver aminotransferases >3 times the upper limit of the reference range (upper normal limit AST or ALT >=40 units/L)

4. History of recurrent urinary tract infection

5. History or current acute or chronic pancreatitis

6. Pregnancy

7. Presence of major contraindications to magnetic resonance imaging (cardiac pacemakers, claustrophobia, foreign bodies and implanted medical devices with ferromagnetic properties).

All patients will be randomized to one of the following intervention groups: Sita group (n = 50): patients with diabetes mellitus receiving multiple doses of insulin plus metformin 500 mg twice daily plus sitagliptin 100 mg once daily and Dapa group (n = 50): patients with diabetes mellitus receiving multiple doses of insulin plus metformin 500 mg daily plus dapagliflozin 10 mg once daily. Glycemic equipoise will be maintained between the two groups by adjusting insulin doses and maintaining target fasting glucose, post-prandial glucose and glycated hemoglobin (HbA1c) in accordance with the ADA 2021.

Imaging Liver fat content and pancreatic fat content will be assessed by magnetic resonance imaging (MRI) proton density fat Fraction (PDFF) at the beginning of study and again after 12 months of intervention. MRI-PDFF is a robust technique for noninvasive quantification of liver fat. Multiple human studies have shown that this method accurately estimates PDFF in the liver. This method has been shown to be both accurate, and reproducible. Investigators have validated this technique for Indian population and is already used in the E-LIFT and D-LIFT trials.

Body composition by Dual energy X-ray absorptiometry (DEXA) Body composition will be assessed by DEXA using the Hologic Horizon DXA System (USA) with Discovery software, version 12.3 (Bellingham, WA, USA). DEXA provides a rapid and non-invasive fat mass, fat free mass and bone mineral density. DEXA is considered to be the reference method for body composition assessment in clinical research. The DEXA-measured body composition variables that will be included for analysis are weight (kg), body mass index (BMI), total fat mass (kg), android fat mass (g), gynoid fat mass (g), visceral adipose tissue (VAT) mass (g), VAT area (cm2), and abdominal subcutaneous adipose tissue (SAT) mass (g). Obesity will be defined as BMI >25 kg/m2 in accordance with World Health Organization (WHO) Asia pacific guidelines. The skeletal muscle mass index (SMI) will be the appendicular skeletal muscle divided by the height in meters squared. Low appendicular skeletal mass index will be defined as <7.0 kg/m2 for men and <5.4 kg/m2 for women, as per Consensus Report of the Asian Working Group for Sarcopenia (AWGS).

Bioelectrical impedance (BIA) analysis Multi-frequency bioelectrical impedance analysis was completed using InBody 570 body composition analyzer (Biospace, Inc. Seoul, Korea). The InBody 570 is a multi-frequency analyzer and divides the body into five components: two arms, two legs, and a trunk. The electrodes are situated beneath the subject's feet on the platform and on the palms and thumbs attached to handles on the device. Age, height and gender are manually entered after weight is determined by a scale positioned within device.

Laboratory workup Biochemical parameters will include fasting plasma glucose, glycosylated hemoglobin (HbA1C), lipid profile, hemogram, kidney function test (urea, creatinine) and liver function test (total and fractionated bilirubin, alanine transaminase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), total protein, albumin) before and after the intervention period.

End points and safety assessments The primary endpoint will be changes from baseline in MRI-PDFF assessed liver and pancreatic fat content at month 12. The secondary outcome measures will be changes from baseline in liver aminotransferases (AST, ALT and GGT) at month 12. Changes from baseline in body composition variables (weight, BMI, body fat percentage, visceral adipose tissue, skeletal muscle mass and bone mineral content) at month 12. Efficacy variables will include proportion of individuals requiring insulin therapy at months 6 and 12, changes from baseline in HbA1c at months 6 and 12, and the percentage change from baseline in the total daily insulin dose (by collecting the daily record of the last week at months 6 and 12). Safety assessment will include adverse events (AEs), serious AEs (SAEs), physical examination findings, vital signs and laboratory values. AEs of special interest will be genital infections, urinary tract infections, volume depletion, fractures, worsening renal function, hepatobiliary AEs, hypersensitivity, and cardiovascular AEs.

Study outcomes The primary outcome measures are

1. Changes from baseline to month 12 in liver and pancreatic fat content. The secondary outcome measures are

1. Change from baseline in body composition variables (body weight, BMI, body fat percentage, visceral adipose tissue, skeletal muscle mass and bone mineral content) at month 12

2. Changes from baseline in liver aminotransferases (AST, ALT and GGT)

3. Changes in efficacy variables (proportion of individuals requiring insulin therapy at months 6 and 12, changes from baseline in HbA1c at months 6 and 12, and the percentage change from baseline in the total daily insulin dose at months 6 and 12).

4. Safety assessment at months 3, 6, 9 and 12 (as described above).

Table 2. Safety summary Characteristic

>=1 AEs >=1 AEs related to the study drug AE leading to study discontinuation AEs of special interest Genital infection Urinary tract infection Renal impairment Fractures Hypotension/dehydration/hypovolemia Hypersensitivity Cardiovascular events SAEs >=1 SAEs >=1 SAEs related to the study drug SAEs leading to study discontinuation Death

Conditions

Diabetes Mellitus; Liver Transplant; Complications

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Dapa Group

Patients with diabetes mellitus will receive dapagliflozin 10 mg once daily. Glycemic equipoise will be maintained between the two groups by adjusting insulin doses and/or metformin and/or sulfonylurea; maintaining target fasting glucose, post-prandial glucose and glycated hemoglobin (HbA1c) in accordance with the ADA 2021

Group Type: ACTIVE_COMPARATOR

Dapagliflozin 10Mg Tab

Intervention Type: DRUG

Dapa group (n = 50): Patients with diabetes mellitus will receive Dapagliflozin 10 mg

Sita Group

Patients with diabetes mellitus will receive sitagliptin 100 mg once daily.Glycemic equipoise will be maintained between the two groups by adjusting insulin doses and/or metformin and/or sulfonylurea; maintaining target fasting glucose, post-prandial glucose and glycated hemoglobin (HbA1c) in accordance with the ADA 2021

Group Type: ACTIVE_COMPARATOR

Sitagliptin 100mg

Intervention Type: DRUG

Sita group (n = 50): Patients with diabetes mellitus will receive sitagliptin 100 mg once daily

Interventions

Dapagliflozin 10Mg Tab

Dapa group (n = 50): Patients with diabetes mellitus will receive Dapagliflozin 10 mg

Intervention Type: DRUG

Sitagliptin 100mg

Sita group (n = 50): Patients with diabetes mellitus will receive sitagliptin 100 mg once daily

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Diagnosis of diabetes (pre-transplantation type 2 diabetes or new onset diabetes after transplantation)

2. Subjects taking insulin and/or metformin and/or sulfonylurea.

3. Body mass index (BMI) >=18.5 kg/m2

Exclusion Criteria

1. Type 1 diabetes

2. Estimated glomerular filtration rate (eGFR) <45 ml/min/1.73 m2, calculated by the Chronic Kidney Disease - Epidemiology (CKD-EPI) equation

3. Liver aminotransferases >3 times the upper limit of the reference range (upper normal limit AST or ALT >=40 units/L)

4. History of recurrent urinary tract infection

5. History or current acute or chronic pancreatitis

6. Pregnancy

7. Presence of major contraindications to magnetic resonance imaging (cardiac pacemakers, claustrophobia, foreign bodies and implanted medical devices with ferromagnetic properties).

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Medanta, The Medicity, India

OTHER

Sponsor Role: lead

Responsible Party

Dr Mohammad Shafi Kuchay

Senior Consultant

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Division Of Endocrinology & Diabetes, Medanta The Medicity

Gurgaon, Haryana, India

Site Status: RECRUITING

Countries

India

Central Contacts

Mr Surender, M.Sc

Role: CONTACT

yadavsurender89@gmail.com

01244141414 ext. 6596

Facility Contacts

Surender, MSc

Role: primary

yadavsurender89@gmail.com

01244141414 ext. 6596

Mohammad Shafi Kuchay, MBBS, MD,DM

Role: backup

drshafikuchay@gmail.com

01244141414 ext. 6596

References

Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab. 2013 Aug;15(8):721-8. doi: 10.1111/dom.12081. Epub 2013 Mar 4.

Reference Type: BACKGROUND

PMID: 23398530 (View on PubMed)

Kuchay MS, Farooqui KJ, Mishra SK, Mithal A. Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors. Adv Exp Med Biol. 2021;1307:213-230. doi: 10.1007/5584_2020_479.

Reference Type: BACKGROUND

PMID: 32006266 (View on PubMed)

Rosenstock J, Seman LJ, Jelaska A, Hantel S, Pinnetti S, Hach T, Woerle HJ. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab. 2013 Dec;15(12):1154-60. doi: 10.1111/dom.12185. Epub 2013 Aug 22.

Reference Type: BACKGROUND

PMID: 23906374 (View on PubMed)

Kuchay MS, Krishan S, Mishra SK, Farooqui KJ, Singh MK, Wasir JS, Bansal B, Kaur P, Jevalikar G, Gill HK, Choudhary NS, Mithal A. Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial). Diabetes Care. 2018 Aug;41(8):1801-1808. doi: 10.2337/dc18-0165. Epub 2018 Jun 12.

Reference Type: BACKGROUND

PMID: 29895557 (View on PubMed)

Reeder SB, Sirlin CB. Quantification of liver fat with magnetic resonance imaging. Magn Reson Imaging Clin N Am. 2010 Aug;18(3):337-57, ix. doi: 10.1016/j.mric.2010.08.013.

Reference Type: BACKGROUND

PMID: 21094444 (View on PubMed)

Reeder SB, Cruite I, Hamilton G, Sirlin CB. Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy. J Magn Reson Imaging. 2011 Oct;34(4):729-749. doi: 10.1002/jmri.22775. Epub 2011 Sep 16.

Reference Type: BACKGROUND

PMID: 22025886 (View on PubMed)

Permutt Z, Le TA, Peterson MR, Seki E, Brenner DA, Sirlin C, Loomba R. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther. 2012 Jul;36(1):22-9. doi: 10.1111/j.1365-2036.2012.05121.x. Epub 2012 May 3.

Reference Type: BACKGROUND

PMID: 22554256 (View on PubMed)

Le TA, Chen J, Changchien C, Peterson MR, Kono Y, Patton H, Cohen BL, Brenner D, Sirlin C, Loomba R; San Diego Integrated NAFLD Research Consortium (SINC). Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology. 2012 Sep;56(3):922-32. doi: 10.1002/hep.25731. Epub 2012 Jul 2.

Reference Type: BACKGROUND

PMID: 22431131 (View on PubMed)

Kuchay MS, Krishan S, Mishra SK, Choudhary NS, Singh MK, Wasir JS, Kaur P, Gill HK, Bano T, Farooqui KJ, Mithal A. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Diabetologia. 2020 Nov;63(11):2434-2445. doi: 10.1007/s00125-020-05265-7. Epub 2020 Aug 31.

Reference Type: BACKGROUND

PMID: 32865597 (View on PubMed)

Krishan S, Jain D, Bathina Y, Kale A, Saraf N, Saigal S, Choudhary N, Baijal SS, Soin A. Non-invasive quantification of hepatic steatosis in living, related liver donors using dual-echo Dixon imaging and single-voxel proton spectroscopy. Clin Radiol. 2016 Jan;71(1):58-63. doi: 10.1016/j.crad.2015.10.002. Epub 2015 Nov 7.

Reference Type: BACKGROUND

PMID: 26555703 (View on PubMed)

Other Identifiers

MMDapa-LiT01

Identifier Type: -

Identifier Source: org_study_id